Disease · MONDO_0011962
endometrial cancer
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. endometrial cancer. Diseases, record MONDO_0011962. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0011962
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
cancer of endometrium, endometrial cancer, familial, autosomal dominant, somatic mutation, endometrial cancer, susceptibility to, autosomal dominant, somatic mutation, endometrial carcinoma, somatic, endometrium cancer, malignant endometrial neoplasm, malignant endometrium neoplasm, malignant neoplasm of endometrium
- Open Targets
Drugs242
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DOSTARLIMAB | CHEMBL4298124 | Antibody | Approval | FDA and TTD | 18 | 16 | 16 | Drugs and targets |
| DOXORUBICIN HYDROCHLORIDE | CHEMBL359744 | Small molecule | Approval | PMDA | 13 | 12 | 12 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 76 | 76 | 75 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 60 | 60 | 60 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 3 | ClinicalTrials.gov | 42 | 42 | 42 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 25 | 25 | 25 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 3 | ClinicalTrials.gov | 22 | 22 | 22 | Drugs and targets |
| LENVATINIB | CHEMBL1289601 | Small molecule | Phase 3 | ClinicalTrials.gov | 18 | 18 | 18 | Drugs and targets |
| OLAPARIB | CHEMBL521686 | Small molecule | Phase 3 | ClinicalTrials.gov | 18 | 18 | 18 | Drugs and targets |
| MEGESTROL ACETATE | CHEMBL1201139 | Small molecule | Phase 3 | ClinicalTrials.gov | 16 | 16 | 16 | Drugs and targets |
1 to 10 of 242
See all 242 drugsTargets235
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDCD1 | Programmed cell death protein 1 | 15 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Approval | https://conductscience.org/library/genes/5133 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 14 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| PIK3CA | PI3-kinase class I | 12 | PI3-kinase class I inhibitor; PI3-kinase p110-alpha subunit inhibitor | Phase 2 | https://conductscience.org/library/genes/5290 | Drugs and targets |
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | 10 | Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-2 negative allosteric modulator; Receptor tyrosine-protein kinase erbB-2 binding agent | Phase 3 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 10 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 9 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| PIK3CD | PI3-kinase class I | 9 | PI3-kinase class I inhibitor; PI3-kinase p110-delta subunit inhibitor | Phase 2 | https://conductscience.org/library/genes/5293 | Drugs and targets |
| MTOR | Serine/threonine-protein kinase mTOR | 8 | Serine/threonine-protein kinase mTOR inhibitor | Phase 2 | https://conductscience.org/library/genes/2475 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 8 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 7 | Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
1 to 10 of 235
See all 235 targetsTrials379
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 9 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00063999 | Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | Phase 3 | 1,381 | 2018-04-23 | Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7 | CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, FILGRASTIM, PACLITAXEL, PEGFILGRASTIM | Its record names the disease | ClinicalTrials.gov |
| NCT03884101 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) | Phase 3 | 842 | 2024-10-16 | Endometrial Neoplasms | LENVATINIB, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03517449 | Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) | Phase 3 | 827 | 2021-11-17 | Endometrial Neoplasms | LENVATINIB, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03914612 | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | Phase 3 | 813 | 2025-03-18 | Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Dedifferentiated Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Mixed Cell Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 | CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04269200 | Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer | Phase 3 | 805 | 2025-12-23 | Endometrial Neoplasms | CARBOPLATIN, DURVALUMAB, OLAPARIB, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT00006011 | Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer | Phase 3 | 659 | 2014-06-26 | Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Serous Adenocarcinoma, Stage III Uterine Corpus Cancer | CISPLATIN, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT00807768 | Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer | Phase 3 | 601 | 2018-04-27 | Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Fatigue, Neurotoxicity Syndrome, Obesity, Stage I Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7 | CARBOPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT00883116 | A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer | Phase 3 | 551 | 2014-03-14 | Endometrial Cancer | DOXORUBICIN, IXABEPILONE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | Phase 1/2 | 515 | 2021-04-06 | Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer | SACITUZUMAB GOVITECAN | Its record names the disease | ClinicalTrials.gov |
| NCT01767155 | Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer | Phase 3 | 511 | 2018-07-31 | Endometrial Cancer | DOXORUBICIN, ZOPTARELIN DOXORUBICIN, ZOPTARELIN DOXORUBICIN ACETATE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 379
See all 379 trialsComparisons in its trials64
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm I (Doxorubicin, Cisplatin, Paclitaxel) vs Arm II (Paclitaxel, Carboplatin): deaths from any cause | 271 of 647 | 280 of 665 | 1,312 | NCT00063999 | Trial comparisons |
| Arm I (Doxorubicin, Cisplatin, Paclitaxel) vs Arm II (Paclitaxel, Carboplatin): serious adverse events | 217 of 647 | 156 of 665 | 1,312 | NCT00063999 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Who Experienced a Serious Adverse Event (SAE) | 230 of 420 | 84 of 411 | 831 | NCT03884101 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Who Discontinued Study Intervention Due to an AE | 203 of 420 | 80 of 411 | 831 | NCT03884101 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Who Experienced an Adverse Event (AE) | 418 of 420 | 405 of 411 | 831 | NCT03884101 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Who Experienced an Immune-Related Adverse Event (irAE) | 316 of 420 | 56 of 411 | 831 | NCT03884101 | Trial comparisons |
Lenvatinib 20 mg + Pembrolizumab 200 mg vs Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel: Number of Participants Who Discontinued Study Treatment Due to a TEAE in All-comer Participants | 180 of 406 | 49 of 388 | 794 | NCT03517449 | Trial comparisons |
Lenvatinib 20 mg + Pembrolizumab 200 mg vs Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel: Number of Partricipants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Immune-Related Adverse Events (irAEs) | 237 of 406 | 121 of 388 | 794 | NCT03517449 | Trial comparisons |
| Lenvatinib 20 mg + Pembrolizumab 200 mg vs Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel: Number of Participants Who Discontinued Study Treatment Due to a TEAE in pMMR Participants | 140 of 342 | 42 of 325 | 667 | NCT03517449 | Trial comparisons |
| Arm I (Pelvic Radiation Therapy) vs Arm II (Brachytherapy, Paclitaxel, Carboplatin): Number of Participants With Recurrence or Death Events at Primary Analysis | 44 of 301 | 43 of 300 | 601 | NCT00807768 | Trial comparisons |
1 to 10 of 64
See all 64 comparisons in its trialsPapers from its trials231
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0011962
GET https://conductscience.org/api/diseases/v1/MONDO_0011962/drugs?page=2